Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) price on Friday, December 27, fall -0.54% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $9.20.
A look at the stock’s price movement, the close in the last trading session was $9.25, moving within a range at $8.99 and $9.255. The beta value (5-Year monthly) was 1.456. Turning to its 52-week performance, $10.67 and $4.71 were the 52-week high and 52-week low respectively. Overall, AUPH moved 5.63% over the past month.
Aurinia Pharmaceuticals Inc’s market cap currently stands at around $1.32 billion, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 59.94M for the company’s revenue for the quarter, with a low and high estimate of 57.75M and 60.81M respectively. The average forecast suggests up to a 32.93% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 235.54M, representing a 34.20% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that AUPH is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 2 recommend AUPH as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
AUPH’s current price about -0.44% and 9.64% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 54.44, while 7-day volatility ratio is 2.63% and 4.15% in the 30-day chart. Further, Aurinia Pharmaceuticals Inc (AUPH) has a beta value of 1.26, and an average true range (ATR) of 0.36. Analysts have given the company’s stock an average 52-week price target of $13, forecast between a low of $13 and high of $13. Looking at the price targets, the low is -41.3% off current price level while to achieve the yearly target high, price needs to move -41.3%. Nonetheless, investors will most likely welcome a -41.3% jump to $13 which is the analysts’ median price.
If we refocus on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), historical trading data shows that trading volumes averaged 1.13 over the past 10 days and 1.25 million over the past 3 months. The company’s latest data on shares outstanding shows there are 143.11 million shares.
The 10.06% of Aurinia Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 39.43% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.22 million on 2024-11-29, giving us a short ratio of 4.22. The data shows that as of 2024-11-29 short interest in Aurinia Pharmaceuticals Inc (AUPH) stood at 437.0 of shares outstanding, with shares short falling to 7.34 million registered in 2024-10-31. Current price change has pushed the stock 2.34% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AUPH stock continues to rise going into the next quarter.
